LAM Pharmaceutical Signs Sales Representative Agreement with SRI, Inc

LAM Pharmaceutical Signs Sales Representative Agreement with SRI, Inc

Business Editors

LEWISTON, N.Y.–(BUSINESS WIRE)–March 24, 2003

LAM Pharmaceutical, Corp. (OTC BB: LAMP; Frankfurt: LAM; Berlin: LAM) www.lampharm.com, a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced the signing of a sales representative agreement with SRI, Inc.

Under this non-exclusive agreement, SRI will promote and maximize the sale of LAM Pharmaceutical’s products.

SRI, Inc. is a marketing and business development company that specializes in healthcare and pharmaceuticals. SRI is headquartered in Franklin Lakes, New Jersey with associates in New York City; Atlanta, Georgia; Denver, Colorado and London, England. SRI assists healthcare companies like LAM in expanding strategic distribution channels. Working with SRI, LAM will be able to take full advantage of SRI’s special relationships and knowledge of both large purchasing group contracts and large corporate hospital buying groups.

“With the appointment of SRI comes the fulfillment of another key foundation step for L.A.M. SRI’s expertise in the area of pharmaceutical sales will position the Company very well as we continue to promote L.A.M. IPM Wound Gel(TM)”, stated Joseph T. Slechta, President & CEO of LAM Pharmaceutical. “We are very pleased to be working with SRI,” concluded Slechta.

“We are excited about this relationship. We are confident that the strength of LAM Pharmaceutical’s product portfolio and SRI’s extensive network, both domestically and internationally, will bring value to both organizations,” stated Richard Craine, Senior VP of Sales and Marketing of SRI, Inc.

Statements in this press release regarding our business, which are not historical facts, are “forward-looking statements” that involve risks and uncertainties which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.

L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.

COPYRIGHT 2003 Business Wire

COPYRIGHT 2003 Gale Group